List view / Grid view
8 August 2016 | By New England Biolabs, Inc.
Novel target enrichment technology, compatible with low input amounts from challenging sample types, uses a one-day workflow...
8 August 2016 | By Merck
Under the FDA’s accelerated approval regulations, Keytruda, a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells, is approved based on tumour response rate and durability of response. However, continued approval for the drug may be contingent upon…
8 August 2016 | By Bristol-Myers Squibb
The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access…
5 August 2016 | By Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, a clinical stage biopharmaceutical company, has been granted orphan drug designations for both its T-cell therapy product candidate BPX-501 for treatment in hematopoietic stem cell transplantation (HSCT), and for activator agent rimiducid...
5 August 2016 | By Erasmus MC University
A new study has revealed that 70% of eczema patients are colonised with Staphylococcus aureus bacteria (S. aureus, including MRSA) on their skin lesions...
4 August 2016 | By National Institute for Health and Care Excellence (NICE)
The National Institute for Health and Care Excellence (NICE) has recommended innovative new drug secukinumab for treating ankylosing spondylitis, a type of arthritis that mainly affects the back....
4 August 2016 | By Niamh Louise Marriott, Digital Content Producer
The PISCES I study was the first clinical trial of ReNeuron’s CTX cell therapy candidate for patients with motor disability as a consequence of ischaemic stroke. The data, collated over two years relates to the eleven stroke patients treated in the study...
3 August 2016 | By Prothena Corporation plc
Prothena Corporation plc has reported financial results for the second quarter and first six months of 2016. In addition, the Company provided an update on its R&D programs and 2016 financial guidance...
3 August 2016 | By RedHill Biopharma Ltd.
The last patient visit has been completed in the Phase IIa study evaluating RHB-104 in patients treated for relapsing-remitting multiple sclerosis (RRMS)...
Gold-silver alloy on SERS substrates detects trace level explosives and pesticides...
2 August 2016 | By GlobalData
The atrial fibrillation market will expand from approximately $8 billion in 2015 to hit its peak of $11.8 billion in 2022, after which the impact of patent expiries will see the market value fall rapidly to $4.9 billion by 2025, according to research and consulting firm GlobalData...
2 August 2016 | By Abeona Therapeutics Inc
Abeona Therapeutics provides an update on its first Sanfilippo patient and reports that early biopotency signals suggest a reduction of heparan sulfate in the urine of patients and if confirmed will suggest that intravenous administration of ABO-102 may ultimately provide both central nervous system and systemic benefits to patients...
2 August 2016 | By PharmaMar
PharmaMar announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 (lurbinectedin) in combination with doxorubicin versus topotecan or the combination VCR (cyclophosphamide, adriamicine (doxorubicin) and vincristine) in patients with small cell lung cancer after the failure of one prior platinum-containing line.
2 August 2016 | By Takeda Pharmaceutical Company Limited / TiGenix NV
Takeda and TiGenix announce that the results of the Phase 3 ADMIRE-CD trial investigating Cx601 have been published. Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn's disease...
1 August 2016 | By Takeda Pharmaceutical Company Ltd and Seattle Genetics, Inc.
Takeda and Seattle Genetics announce that the ALCANZA trial evaluating ADCETRIS for cutaneous T-cell lymphoma demonstrated significant improvement...
